Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
Abstract Aims/Introduction To evaluate the efficacy and safety of once‐weekly (q.w.) extended‐release exenatide after switching from twice‐daily (b.i.d.) exenatide in patients with type 2 diabetes. Materials and Methods This was an investigator‐initiated, prospective, single‐arm, multicenter study....
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-03-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.13146 |
| _version_ | 1818936980557266944 |
|---|---|
| author | Yuusuke Watanabe Yoshifumi Saisho Jun Inaishi Kinsei Kou Akira Yamauchi Yasuhiko Kanazawa Yoshiaki Okubo Mikiya Tokui Takatoshi Imai Rie Murakami Tami Tsuchiya Hironobu Sasaki Tatsuhiro Masaoka Junichiro Irie Shu Meguro Hiroshi Itoh for the Twin‐exenatide Study Group |
| author_facet | Yuusuke Watanabe Yoshifumi Saisho Jun Inaishi Kinsei Kou Akira Yamauchi Yasuhiko Kanazawa Yoshiaki Okubo Mikiya Tokui Takatoshi Imai Rie Murakami Tami Tsuchiya Hironobu Sasaki Tatsuhiro Masaoka Junichiro Irie Shu Meguro Hiroshi Itoh for the Twin‐exenatide Study Group |
| author_sort | Yuusuke Watanabe |
| collection | DOAJ |
| description | Abstract Aims/Introduction To evaluate the efficacy and safety of once‐weekly (q.w.) extended‐release exenatide after switching from twice‐daily (b.i.d.) exenatide in patients with type 2 diabetes. Materials and Methods This was an investigator‐initiated, prospective, single‐arm, multicenter study. Individuals with type 2 diabetes who had been treated with exenatide b.i.d. for at least 3 months were enrolled and switched to exenatide q.w. for 24 weeks. The primary end‐point was change in HbA1c at week 24 to test the glucose‐lowering effect of exenatide q.w. versus exenatide b.i.d. Results A total of 58 Japanese individuals with type 2 diabetes completed the study. Glycated hemoglobin was reduced by 0.2% at week 24 (7.2 ± 1.2% vs 7.0 ± 1.2% [56 ± 13 vs 53 ± 13 mmol/mol], 95% confidence interval −0.4 to −0.03%, P < 0.005 for non‐inferiority, P = 0.01 for superiority). Fasting plasma glucose was reduced by 12 mg/dL at week 24 (154 ± 46 vs 142 ± 46 mg/dL, P = 0.02). β‐Cell function assessed by homeostasis model assessment of β‐cell function and C‐peptide index was significantly improved at week 24. The incidence of self‐reported hypoglycemia was reduced, and treatment satisfaction assessed by the Diabetes Treatment Satisfaction Questionnaire and Diabetes Medication Satisfaction Questionnaire was improved at week 24, with no change in body weight. There was no serious adverse event related to the study drug. Conclusions Switching from exenatide b.i.d. to exenatide q.w. resulted in a reduction in glycated hemoglobin, fasting plasma glucose and the incidence of hypoglycemia, and improvement in β‐cell function and treatment satisfaction in patients with type 2 diabetes. These findings will be useful for selecting optimal treatment in individuals with type 2 diabetes. |
| first_indexed | 2024-12-20T05:44:41Z |
| format | Article |
| id | doaj.art-adcab71cc04b41e7888471fe5446a704 |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-12-20T05:44:41Z |
| publishDate | 2020-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-adcab71cc04b41e7888471fe5446a7042022-12-21T19:51:21ZengWileyJournal of Diabetes Investigation2040-11162040-11242020-03-0111238238810.1111/jdi.13146Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetesYuusuke Watanabe0Yoshifumi Saisho1Jun Inaishi2Kinsei Kou3Akira Yamauchi4Yasuhiko Kanazawa5Yoshiaki Okubo6Mikiya Tokui7Takatoshi Imai8Rie Murakami9Tami Tsuchiya10Hironobu Sasaki11Tatsuhiro Masaoka12Junichiro Irie13Shu Meguro14Hiroshi Itoh15for the Twin‐exenatide Study GroupDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanHiratsuka City Hospital Kanagawa JapanSuruga Clinic Shizuoka JapanKawasaki Municipal Ida Hospital Kanagawa JapanTokyo Dental College Ichikawa General Hospital Chiba JapanTokui Clinic Kanagawa JapanYokohama Municipal Citizen's Hospital Kanagawa JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Gastroenterology and Hepatology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanDepartment of Internal Medicine Division of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo JapanAbstract Aims/Introduction To evaluate the efficacy and safety of once‐weekly (q.w.) extended‐release exenatide after switching from twice‐daily (b.i.d.) exenatide in patients with type 2 diabetes. Materials and Methods This was an investigator‐initiated, prospective, single‐arm, multicenter study. Individuals with type 2 diabetes who had been treated with exenatide b.i.d. for at least 3 months were enrolled and switched to exenatide q.w. for 24 weeks. The primary end‐point was change in HbA1c at week 24 to test the glucose‐lowering effect of exenatide q.w. versus exenatide b.i.d. Results A total of 58 Japanese individuals with type 2 diabetes completed the study. Glycated hemoglobin was reduced by 0.2% at week 24 (7.2 ± 1.2% vs 7.0 ± 1.2% [56 ± 13 vs 53 ± 13 mmol/mol], 95% confidence interval −0.4 to −0.03%, P < 0.005 for non‐inferiority, P = 0.01 for superiority). Fasting plasma glucose was reduced by 12 mg/dL at week 24 (154 ± 46 vs 142 ± 46 mg/dL, P = 0.02). β‐Cell function assessed by homeostasis model assessment of β‐cell function and C‐peptide index was significantly improved at week 24. The incidence of self‐reported hypoglycemia was reduced, and treatment satisfaction assessed by the Diabetes Treatment Satisfaction Questionnaire and Diabetes Medication Satisfaction Questionnaire was improved at week 24, with no change in body weight. There was no serious adverse event related to the study drug. Conclusions Switching from exenatide b.i.d. to exenatide q.w. resulted in a reduction in glycated hemoglobin, fasting plasma glucose and the incidence of hypoglycemia, and improvement in β‐cell function and treatment satisfaction in patients with type 2 diabetes. These findings will be useful for selecting optimal treatment in individuals with type 2 diabetes.https://doi.org/10.1111/jdi.13146Glucagon‐like peptide‐1 receptor agonistTreatment satisfactionType 2 diabetes |
| spellingShingle | Yuusuke Watanabe Yoshifumi Saisho Jun Inaishi Kinsei Kou Akira Yamauchi Yasuhiko Kanazawa Yoshiaki Okubo Mikiya Tokui Takatoshi Imai Rie Murakami Tami Tsuchiya Hironobu Sasaki Tatsuhiro Masaoka Junichiro Irie Shu Meguro Hiroshi Itoh for the Twin‐exenatide Study Group Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes Journal of Diabetes Investigation Glucagon‐like peptide‐1 receptor agonist Treatment satisfaction Type 2 diabetes |
| title | Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes |
| title_full | Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes |
| title_fullStr | Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes |
| title_full_unstemmed | Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes |
| title_short | Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes |
| title_sort | efficacy and safety of once weekly exenatide after switching from twice daily exenatide in patients with type 2 diabetes |
| topic | Glucagon‐like peptide‐1 receptor agonist Treatment satisfaction Type 2 diabetes |
| url | https://doi.org/10.1111/jdi.13146 |
| work_keys_str_mv | AT yuusukewatanabe efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT yoshifumisaisho efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT juninaishi efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT kinseikou efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT akirayamauchi efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT yasuhikokanazawa efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT yoshiakiokubo efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT mikiyatokui efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT takatoshiimai efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT riemurakami efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT tamitsuchiya efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT hironobusasaki efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT tatsuhiromasaoka efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT junichiroirie efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT shumeguro efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT hiroshiitoh efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes AT forthetwinexenatidestudygroup efficacyandsafetyofonceweeklyexenatideafterswitchingfromtwicedailyexenatideinpatientswithtype2diabetes |